Click for Menu of Articles
research-review:efficacy-and-safety-of-voretigene-neparvovec-phase3
This is an old revision of the document!
Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849-860. doi:10.1016/S0140-6736(17)31868-8
Schultz BR, Chamberlain JS. Recombinant adeno-associated virus transduction and integration. Mol Ther. 2008;16(7):1189-1199. doi:10.1038/mt.2008.103
research-review/efficacy-and-safety-of-voretigene-neparvovec-phase3.1574359204.txt.gz · Last modified: 2019/11/21 18:00 by danny
Except where otherwise noted, content on this wiki is licensed under the following license: CC Attribution-Share Alike 4.0 International
